Effect and Safety of Radiation Therapy Boost to Extramesorectal Lymph Nodes in Rectal Cancer

Chen, Haihui; Nguyen, K.N.B.; Huang, Haixin; Feng, Chengjun; Zhao, Xiao; Daly, Megan E.; Rao, Shyam; Fragoso, R; Valicenti, Richard K.; Sekhon, Simran; Navarro, Shannon M.; Kim, Edward; Cho, May; Tam, Kit; Farkas, Linda M.; Halabi, Wissam J.; Monjazeb, Arta M.; Rong, Yi

doi:10.1016/j.prro.2019.12.007

Cited by 10 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only two studies have reported on dose-escalation very small patient cohorts. The first study provided an additional boost to clinically positive LLNs of 54.0-59.4Gy at 1.8Gy/fraction, while the second study delivered 53.48-60.2Gy in 27-30 fractions (1.8-2.15Gy/fraction) to clinically suspicious LLNs (48,49). Both found similar local-control rates for patients who did and did not receive a boost.…”

Section: Radiation Oncologymentioning

confidence: 99%

Lateral Lymph Nodes in Rectal Cancer: Do we all Think the Same? A Review of Multidisciplinary Obstacles and Treatment Recommendations

Sluckin¹,

Couwenberg²,

Lambregts³

et al. 2022

Clinical Colorectal Cancer

View full text Add to dashboard Cite

Section: Radiation Oncologymentioning

confidence: 99%

Lateral Lymph Nodes in Rectal Cancer: Do we all Think the Same? A Review of Multidisciplinary Obstacles and Treatment Recommendations

Sluckin¹,

Couwenberg²,

Lambregts³

et al. 2022

Clinical Colorectal Cancer

View full text Add to dashboard Cite

“…Local control at 12 months was 90%, and the treatment was well-tolerated with a low risk of acute toxicity and perioperative complications. Chen et al compared the oncological outcomes between non-boost and boost groups (62). The non-boost group contained patients without clinically involved LPLN who received NCRT with 50.4 Gy in 28 fractions.…”

Section: Management Of Lpln Metastasis: Radiation Therapymentioning

confidence: 99%

“…Chen et al. compared the oncological outcomes between non-boost and boost groups ( 62 ). The non-boost group contained patients without clinically involved LPLN who received NCRT with 50.4 Gy in 28 fractions.…”

Section: Management Of Lpln Metastasis: Radiation Therapymentioning

confidence: 99%

Clinical implication and management of rectal cancer with clinically suspicious lateral pelvic lymph node metastasis: A radiation oncologist’s perspective

Yoo

Park

2022

Front. Oncol.

View full text Add to dashboard Cite

Rectal cancer is the eighth most common malignancy worldwide. With the introduction of total mesorectal excision (TME) and neoadjuvant chemoradiation (NCRT), intrapelvic local control has been remarkably improved. However, lateral pelvic recurrence remains problematic, especially in patients with clinically suspicious lateral pelvic lymph node (LPLN). LPLN dissection has been applied for the management of LPLN metastasis, mainly in Japan and other Eastern countries, while the role of NCRT is more emphasized and LPLN dissection is performed in very limited cases in Western countries. However, the optimal management strategy for patients with rectal cancer with suspicious LPLN metastasis has not been determined. Herein, we review the latest studies on the optimal management of LPLN metastasis to suggest the most appropriate treatment policies according to current evidence and discuss future research directions.

show abstract

“…Some Western clinicians believe that an irradiation boost may provide the extra enhancement required to treat LLNs without additional LLND surgery. 52 , 53 , 54 Just two studies have evaluated a boost in LLNs, with mixed results. Chen et al 53 studied 12 patients with suspicious LLNs, all of which had received a “boost” as treatment (3 × 5.4 Gy).…”

Section: Towards International Collaborationmentioning

confidence: 99%

“… 52 , 53 , 54 Just two studies have evaluated a boost in LLNs, with mixed results. Chen et al 53 studied 12 patients with suspicious LLNs, all of which had received a “boost” as treatment (3 × 5.4 Gy). They were compared to 41 patients without LLNs who received standard CRT (25 × 1.8 Gy).…”

Section: Towards International Collaborationmentioning

confidence: 99%

From “East vs West” towards international multidisciplinary collaboration: An appraisal of lateral lymph nodes in rectal cancer

Sluckin

Hazen

Kusters

2021

Annals of Gastroent Surgery

View full text Add to dashboard Cite

Western and Eastern practices have traditionally differed in their approach to treating lateral lymph nodes in rectal cancer. While Western clinicians have primarily favored neoadjuvant (chemo)radiotherapy to sterilize lateral compartments, Eastern physicians have often opted for the surgical removed of lymphatic tissue with a lateral lymph node dissection without neoadjuvant treatment. The literature suggests similar oncological outcomes for these two separate techniques, while tangible differences exist. The combination of these paradigms may be beneficial in reducing overall morbidity while sustaining low recurrence rates. This article considers traditional Eastern and Western perspectives, discusses nodal features important for predicting malignancy and attempts to stimulate international, multidisciplinary consensus and collaboration.

show abstract

Effect and Safety of Radiation Therapy Boost to Extramesorectal Lymph Nodes in Rectal Cancer

Cited by 10 publications

References 20 publications

Lateral Lymph Nodes in Rectal Cancer: Do we all Think the Same? A Review of Multidisciplinary Obstacles and Treatment Recommendations

Lateral Lymph Nodes in Rectal Cancer: Do we all Think the Same? A Review of Multidisciplinary Obstacles and Treatment Recommendations

Clinical implication and management of rectal cancer with clinically suspicious lateral pelvic lymph node metastasis: A radiation oncologist’s perspective

From “East vs West” towards international multidisciplinary collaboration: An appraisal of lateral lymph nodes in rectal cancer

Contact Info

Product

Resources

About